Thienopyridinone derivatives as macrophage migration...

Details Thienopyridinone derivatives as macrophage migration... Thienopyridinone derivatives as macrophage migration...

2008-04-29

2008-04-29

Bernhardt, Emily (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

C514S253040

Reexamination Certificate

active

11687598

ABSTRACT:
Inhibitors of macrophage migration inhibitory factor having a thienopyridinone backbone are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with macrophage migration inhibitory factor activity. The inhibitors of macrophage migration inhibitory factor have the following structures:including forms such as stereoisomers, free forms, pharmaceutically acceptable salts or esters thereof, solvates, or combinations of such forms, wherein n, R1, R2, R3, X, and Y are as defined herein. Compositions comprising an inhibitor of macrophage migration inhibitory factor in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

REFERENCES:
patent: 4284768 (1981-08-01), Santilli
patent: 4299814 (1981-11-01), Brandt et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4708937 (1987-11-01), Remold
patent: 5246869 (1993-09-01), Potter et al.
patent: 5328990 (1994-07-01), Wistow
patent: 5350687 (1994-09-01), Odink et al.
patent: 5352660 (1994-10-01), Pawson
patent: 5411882 (1995-05-01), Odink et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5597708 (1997-01-01), Holder et al.
patent: 5650295 (1997-07-01), Li et al.
patent: 5656596 (1997-08-01), Monard et al.
patent: 5656737 (1997-08-01), Wistow
patent: 5683887 (1997-11-01), Bucala et al.
patent: 5700447 (1997-12-01), Bucala et al.
patent: 5702920 (1997-12-01), Odink et al.
patent: 5733524 (1998-03-01), Bucala et al.
patent: 5733546 (1998-03-01), Bucala et al.
patent: 5733933 (1998-03-01), Bucala et al.
patent: 5780615 (1998-07-01), Bucala et al.
patent: 5801200 (1998-09-01), Bucala et al.
patent: 5821336 (1998-10-01), Odink et al.
patent: 5869534 (1999-02-01), Bucala et al.
patent: 5883224 (1999-03-01), Kirkpatrick et al.
patent: 5919815 (1999-07-01), Bradley et al.
patent: 5986060 (1999-11-01), Li et al.
patent: 6028081 (2000-02-01), Sada et al.
patent: 6030615 (2000-02-01), Bucala et al.
patent: 6080407 (2000-06-01), Bucala et al.
patent: 6214343 (2001-04-01), Kink et al.
patent: 6238874 (2001-05-01), Jarnagin et al.
patent: 6413939 (2002-07-01), Bucala et al.
patent: 6420188 (2002-07-01), Bucala et al.
patent: 7084141 (2006-08-01), Gaeta et al.
patent: 7105519 (2006-09-01), Gaeta et al.
patent: 2003/0195194 (2003-10-01), Gaeta et al.
patent: 2004/0019921 (2004-01-01), Fingerle-Rowson et al.
patent: 2004/0204586 (2004-10-01), Sircar et al.
patent: 2005/0124604 (2005-06-01), Sircar et al.
patent: 2006/0094727 (2006-05-01), Gaeta et al.
patent: 592753 (1985-11-01), None
patent: 0020090 (1980-12-01), None
patent: 0162812 (1985-05-01), None
patent: 0154454 (1985-09-01), None
patent: 0263072 (1988-04-01), None
patent: 0412050 (1991-02-01), None
patent: 0900789 (1999-10-01), None
patent: 1424336 (2004-06-01), None
patent: 1500402 (2005-01-01), None
patent: WO 80/02287 (1980-10-01), None
patent: WO 90/11301 (1990-10-01), None
patent: WO 94/20083 (1994-09-01), None
patent: WO 94/26307 (1994-11-01), None
patent: WO 96/09389 (1996-03-01), None
patent: WO 96/15242 (1996-05-01), None
patent: WO 97/29635 (1997-08-01), None
patent: WO 97/39326 (1997-10-01), None
patent: WO 97/40159 (1997-10-01), None
patent: WO 98/17314 (1998-04-01), None
patent: WO 99/29894 (1999-06-01), None
patent: WO 01/32606 (2001-05-01), None
patent: WO 02/07720 (2002-01-01), None
patent: WO 02/067862 (2002-09-01), None
patent: WO 02/079517 (2002-10-01), None
patent: WO 03/065979 (2003-08-01), None
patent: WO 03/104178 (2003-12-01), None
patent: WO 03/104203 (2003-12-01), None
patent: WO 2004/060881 (2004-07-01), None
patent: WO 2004/076679 (2004-09-01), None
Vippagunta et al Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).
Abe et al. 1993. “Induction of Vascular Endothelial Tublar Morphogenesis by Human Glioma Cells.”J. Clin. Invest.92:54.
Abe et al. 2001. “Regulation of the CTL Response by Macrophage Migration Inhibitory Factor.”J. Immunol.166:747-753.
Archer et al. 1983. “Electrophilic Aromatic Substitution. Part 34. Partial Rate Factors for Detritiation of Dithieno [1,2-b:4,3-b'] benzene, Dithieno[1,2-b:3,4-b'] benzene, and Dithieno [2,1-b:3,4-b']benzene.”J. Chem. Soc. Perkin Trans. II.813-819.
Aroca et al. 1991. “Specificity of dopachrome tautomerase and inhibition by carboxylated indoles.”Biochem. J.277:393-397.
Ausubel et al. 1987.Current Protocols in Molecular Biology. Ausubel et al.(ed.) John Wiley & Sons, Inc.
Bacher et al. 1998. “MIF Expression in the Rat Brain: Implications for Neuronal Function.”Mol. Med.4(4):217-230.
Baugh et al. 2002. “Macrophage migration inhibitory factor.”Crit. Care Med.30(1 Suppl.):S27-S35.
Bernhagen et al. 1995. “The emerging role of MIF in septic shock and infection.”Biotherapy8(2):123-7.
Bernhager et al. 1993. “MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia.”Nature365:756-759.
Bernhagen et al. 1994. “Macrophage migration inhibitory factor is a neuroendocrine mediator of endotoxaemia.”Trends Microbiol. 2:198-201.
Bernhagen et al. 1998. “Regulation of the immune response by macrophage migration inhibitory factor: biological and structural features.”J. Mol. Med.76(3-4):151-161.
Bianchi et al. 1999. “Conformational Changes in Human Hepatitis C Virus NS3 Protease upon Binding of Product-Based Inhibitors.”Biochem.38(42): 13844-13852.
Blocki et al. 1992. “Rat liver protein linking chemical and immunological detoxification systems.”Nature360:269-270.
Blocki et al. 1993. “MIF proteins are theta-class glutathione S-transferase homologs.”Protein Science2:2095-2102.
Bone et al. 1987. “A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock.” N. Eng. J. Med. 317: 653-658.
Bucala. 1994. “MIF, a Previously Unrecognized Pituitary Hormone and Macrophage Cytokine, Is a Pivotal Mediator in Endotoxic Shock.”Circulatory Shock44(1):35-39.
Bucala. 1996. “MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response.”FASEB J.10(14):1607-1613.
Bucala. 1998. “Neuroimmunomodulation by Macrophage Migration Inhibitory Factor (MIF).”Ann. N. Y. Acad. Sci.840:74-82.
Bucala. 2000. “A most interesting factor.”Nature408:146-147.
Calandra et al. 1996. “Macrophage Migration Inhibitory Factor: A Counter-Regulator of Glucocorticoid Action and Critical Mediator of Septic Shock.”J. Inflammation47:39-51.
Calandra et al. 1997. “Macrophage Migration Inhibitory Factor (MIF): A Glucocorticoid Counter-Regulator within the Immune System.”Crit. Rev. Immunol.17(1):77-88.
Calandra et al. 1994. “The Macrophage Is an Important and Previously Unrecognized Source of Macrophage Migration Inhibitory Factor.”J. Exp. Med.179:1895-1902.
Calandra et al. 1995. “MIF as a glucocorticoid-induced modulator of cytokine production.”Nature377:68-71.
Calandra et al. 2000. “Protection from septic shock by neutralization of macrophage migration inhibitory factor.”Nature Medicine6(2):164-170.
Carceller et al. 1993. “Synthesis and Structure-Activity Relationships of 1-Acyl-4((2-methyl-3-pyridyl)cyanomethyl)piperaines as PAF Antagonists.”J. Med. Chem.36:2984-2997.
Carvajal et al. 1982. “Cell-Mediated Immunity Against Connective Tissue in Experimental Pulmonary Fibrosis.”Lung160(3): 131-40.
Chesney et al. 1999. “An Essential Role for Macrophage Migration Inhibitory Factor (MIF) in Angiogenesis and the Growth of a Murine Lymphoma.”Mol. Med.5: 181-191.
Coppola, et al.; Transformation in the 2-Quinolone Series, Journal of Heterocyclic Chemistry, August 1981, vol. 18, No. 5, pp. 917-920.
Dandliker et al. 1970. “Fluorescence polarization in Immunochemistry.”Immunochem.7:799-828.
Donnelly et al. 1997. “Macrophage migration inhibitory factor: a regulator of glucocor

Affiliated with

Also associated with

Rating

Thienopyridinone derivatives as macrophage migration... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Thienopyridinone derivatives as macrophage migration..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thienopyridinone derivatives as macrophage migration... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3912038